Select Page

We move prostate cancer diagnostic forward

Biological fluid analytics

Biomarker discovery and validation company

PROSTATE CANCER RISK STRATIFICATION TEST

Prostate cancer is one of the most frequent cancers globally. 1 out of 8 men will develop prostate cancer once in their lifetime. High incidence of the disease makes a reliable early diagnostic vital for better treatment outcomes. Current prostate cancer detection pathway is still very inaccurate and leads in over half of the cases to unnecessary prostate biopsies, where no cancer is found.

Cambridge Oncometrix has developed a revolutionary non-invasive pre-biopsy diagnostic test that allows for much-improved prostate cancer risk assessment in primary and secondary care.

About

Cambridge Oncometrix test will aid identification of men suspected of prostate cancer who can safely forgo prostate biopsy. We aim to reduce the number of unnecessary prostate biopsies by 50%.

Our test:

 

  • Reduces the number of prostate biopsies
  • Saves lives through earlier prostate cancer detection
  • Decreases healthcare costs
  • Improves patient experience and treatment outcomes

Funding and awards

AWARD WINNING

FUNDED BY

For more information contact us